Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer immunology research

• Publication date

  2014-11-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-14-0036PMID 25370534PMCID PMC4323929
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ResearchTasquinimod ( ABR-215050 ) , a quinoline-3-carboxamide anti-angiogenic agent , modulates the expression of thrombospondin-1 in human prostate tumors

  2015cited by this paper
• Mechanisms of action of tasquinimod on the tumour microenvironment

  2013cited by this paper
• Induction of myelodysplasia by myeloid-derived suppressor cells.

  2013cited by this paper
• Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.

  2013cited by this paper
• Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

  2013cited by this paper
• Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.

  2013cited by this paper
• Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

  2013cited by this paper
• Macrophage regulation of tumor responses to anticancer therapies.

  2013cited by this paper
• A CXCL1 paracrine network links cancer chemoresistance and metastasis.

  2012cited by this paper
• Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

  2012cited by this paper
• Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline‐3‐carboxamide tasquinimod (ABR‐215050)

  2012cited by this paper
• Development of a castrate resistant transplant tumor model of prostate cancer

  2012cited by this paper
• Monotherapeutically Nonactive CTLA-4 Blockade Results in Greatly Enhanced Antitumor Effects When Combined With Tumor-targeted Superantigens in a B16 Melanoma Model

  2012cited by this paper
• S100A9 Interaction with TLR4 Promotes Tumor Growth

  2012cited by this paper
• Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

  2012cited by this paper
• Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

  2012cited by this paper
• Mesenchymal Transition and Dissemination of Cancer Cells Is Driven by Myeloid-Derived Suppressor Cells Infiltrating the Primary Tumor

  2011cited by this paper
• Antigen specificity of immune suppression by myeloid‐derived suppressor cells

  2011cited by this paper
• Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

  2011cited by this paper
• Modulators of Arginine Metabolism Do Not Impact on Peripheral T-Cell Tolerance and Disease Progression in a Model of Spontaneous Prostate Cancer

  2011cited by this paper
• Ipilimumab: A Novel Treatment for Metastatic Melanoma

  2011cited by this paper
• S100A8/A9 Activate Key Genes and Pathways in Colon Tumor Progression

  2011cited by this paper
• Myeloid-derived suppressor cell heterogeneity and subset definition.

  2010cited by this paper
• Mast Cells Mobilize Myeloid-Derived Suppressor Cells and Treg Cells in Tumor Microenvironment via IL-17 Pathway in Murine Hepatocarcinoma Model

  2010cited by this paper
• Antitumor cytotoxic T-cell response induced by a survivin peptide mimic

  2010cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site.

  2009cited by this paper
• Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

  2009cited by this paper
• Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

  2008cited by this paper
• The role of myeloid cells in the promotion of tumour angiogenesis

  2008cited by this paper
• Toll-like receptor–induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens

  2008cited by this paper
• Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1

  2008influential reference
• Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

  2008cited by this paper
• Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

  2008influential reference
• Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function.

  2008cited by this paper
• Altered macrophage differentiation and immune dysfunction in tumor development.

  2007cited by this paper
• The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

  2007cited by this paper
• Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.

  2007cited by this paper
• Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis

  2006cited by this paper
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

  2006cited by this paper
• Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer

  2006cited by this paper
• Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

  2006cited by this paper
• Macrophages direct tumour histology and clinical outcome in a colon cancer model

  2005cited by this paper
• Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

  2005cited by this paper
• VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

  2005cited by this paper
• CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1

  2005cited by this paper
• Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.

  2004cited by this paper
• Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.

  2002cited by this paper
• M-1/M-2 Macrophages and the Th1/Th2 Paradigm1

  2000cited by this paper
• Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.

  1994cited by this paper
• V beta-specific stimulation of human T cells by staphylococcal toxins.

  1989cited by this paper
• Immunology of spontaneous mammary carcinomas in mice. 3. Immunogenicity of C3H preneoplastic hyperplastic alveolar nodules in C3Hf hosts.

  1966cited by this paper
• Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus.

  1966cited by this paper
• Spontaneous regression of primary malignant melanomas with regional metastases

  1965influential reference

• Lung cancer-fueled emergency myelopoiesis is characterized by an increase of S100A9+ and LCN2+ hematopoietic stem and progenitor cells

  2026influential citation
• Macrophage-derived S100A9 drives liver fibrosis in Echinococcus multilocularis infection by up-regulating secreted protein acidic and rich in cysteine (SPARC) in hepatic stellate cells.

  2026cites this paper
• Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design

  2025cites this paper
• Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance mechanisms in prostate cancer.

  2025cites this paper
• Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies.

  2025cites this paper
• Tumor-associated macrophages in colorectal cancer metastasis: molecular insights and translational perspectives

  2024cites this paper
• Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer

  2024cites this paper
• Multifaceted roles of neutrophils in tumor microenvironment.

  2024cites this paper
• Biological Roles and Clinical Therapeutic Applications of Tumor-Associated Macrophages in Colorectal Liver Metastasis

  2024cites this paper
• Blocking S100A9-signaling is detrimental to the initiation of anti-tumor immunity

  2024cites this paper
• S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling

  2024cites this paper
• S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes

  2023cites this paper
• Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment

  2023cites this paper
• Third generation quinoline‐3‐carboxamide transcriptional disrupter of HDAC4, HIF‐1α, and MEF‐2 signaling for metastatic castration‐resistant prostate cancer

  2023influential citation
• Macrophage’s role in solid tumors: two edges of a sword

  2023influential citation
• Non-coding RNAs: emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer.

  2023cites this paper
• Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma

  2023cites this paper
• Cutting the umbilical cord: Cancer stem cell-targeted therapeutics.

  2022cites this paper
• Single-cell RNA sequencing unveils the communications between malignant T and myeloid cells contributing to tumor growth and immunosuppression in cutaneous T-cell lymphoma.

  2022cites this paper
• S100A9 Derived from Chemoembolization‐Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression

  2022cites this paper
• Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation

  2022cites this paper
• Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

  2022cites this paper
• Prostate cancer immunotherapy

  2022cites this paper
• Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?

  2022cites this paper
• Neutrophils as potential therapeutic targets in hepatocellular carcinoma

  2022cites this paper
• Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis

  2021cites this paper
• Role of RAGE and Its Ligands on Inflammatory Responses to Brain Tumors

  2021cites this paper
• The evolving role of immune cells in prostate cancer.

  2021cites this paper
• Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy

  2021cites this paper
• Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer

  2021cites this paper
• The Enigma of Low-Density Granulocytes in Humans: Complexities in the Characterization and Function of LDGs during Disease

  2021cites this paper
• Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers

  2021cites this paper
• Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils

  2020cites this paper
• Friend or Foe: S100 Proteins in Cancer

  2020cites this paper
• Application of Anti-Inflammatory Agents in Prostate Cancer

  2020cites this paper
• Pharmacologic Exhaustion of Suppressor Cells with Tasquinimod Enhances Bacterial Clearance during Tuberculosis

  2019cites this paper
• The Emerging Role of Myeloid-Derived Suppressor Cells in Tuberculosis

  2019cites this paper
• Targeting Tumor Microenvironment by Small-Molecule Inhibitors

  2019cites this paper
• Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity

  2019cites this paper
• A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer.

  2019cites this paper
• Role of Myeloid-Derived Suppressor Cells and Regulatory T-Cells in the Tuberculous Granuloma

  2019cites this paper
• Crosstalk between myeloid‐derived suppressor cells and the immune system in prostate cancer

  2019cites this paper
• Immunoengineering through cancer vaccines – A personalized and multi‐step vaccine approach towards precise cancer immunity

  2018cites this paper
• Promising immunotherapy for prostate cancer

  2018cites this paper
• Myeloid-derived suppressor cells and their role in gynecological malignancies

  2018cites this paper
• The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis

  2018cites this paper
• Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy

  2018cites this paper
• S100A9 in inflammatory disease: a potential target for amelioration

  2018cites this paper
• Dietary Early Glycation Products Promote the Growth of Prostate Tumors More than Advanced Glycation End‐Products through Modulation of Macrophage Polarization

  2018cites this paper
• Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide

  2017cites this paper
• The role of nitric oxide in melanoma.

  2017cites this paper
• The Role of Myeloid-Derived Suppressor Cells in Viral Infection

  2017cites this paper
• Visualisation and monitoring of tumour-mediated immune modulation in primary cancer and premetastatic niche establishment using S100A8/A9-specific imaging

  2017cites this paper
• IL-4Rα aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment

  2017cites this paper
• Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

  2017cites this paper
• Prostate cancer immunotherapy: where are we and where are we going?

  2017cites this paper
• Clinical development of immunotherapy for prostate cancer

  2017cites this paper
• A comprehensive review of immunotherapies in prostate cancer.

  2017cites this paper
• PKCζ in prostate cancer cells represses the recruitment and M2 polarization of macrophages in the prostate cancer microenvironment

  2017cites this paper
• DNA vaccines for prostate cancer.

  2017cites this paper
• Suppression of T cells by myeloid-derived suppressor cells in cancer.

  2017cites this paper
• Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.

  2017cites this paper
• Nanomedicine Strategies to Target Tumor-Associated Macrophages

  2017cites this paper
• A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers

  2017cites this paper
• In neonates S100A8/S100A9 alarmins prevent the expansion of a specific inflammatory monocyte population promoting septic shock

  2017cites this paper
• Myeloid‐derived cells in prostate cancer progression: phenotype and prospective therapies

  2017cites this paper
• The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

  2017cites this paper
• A Perspective of Immunotherapy for Prostate Cancer

  2016cites this paper
• Molecular Mechanisms and Metabolomics of Natural Polyphenols Interfering with Breast Cancer Metastasis

  2016cites this paper
• Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma

  2016cites this paper
• Role of S100 Proteins in Colorectal Carcinogenesis

  2016cites this paper
• Targeting Inflammation in Cancer Prevention and Therapy

  2016cites this paper
• Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination

  2016cites this paper
• Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer

  2016cites this paper
• The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth

  2016cites this paper
• Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment

  2016cites this paper
• Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.

  2016cites this paper
• The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth

  2016cites this paper
• Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets

  2016cites this paper
• Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

  2016cites this paper
• Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment

  2015cites this paper
• Tasquinimod targets suppressive myeloid cells in the tumor microenvironment

  2015cites this paper
• The regulatory role of osteoblasts in castration-resistant growth of prostate cancer

  2015cites this paper
• Correlation between myeloid-derived suppressor cells and S100A8/A9 in tumor and autoimmune diseases.

  2015cites this paper
• Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

  2015influential citation
• Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer

  2015cites this paper